Table of Contents
ISRN Neurology
Volume 2013, Article ID 128591, 6 pages
Clinical Study

Intrathecal Administration of Autologous CD34 Positive Cells in Patients with Past Cerebral Infarction: A Safety Study

1Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an 710054, China
2Alliancells Institute of Stem Cells and Translational Regenerative Medicine & Alliancells Bioscience Co., Ltd., Tianjin 300381, China
3Zhongyuan Union Stem Cell Bioengineering Co., Ltd., Tianjin 300050, China
4Beijing Alliancells-PuRui Bioscience Co., Ltd., Beijing 100052, China
5Department of Cell Biology, Oklahoma State University, Tulsa, OK 74106, USA
6Harold Hamm Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received 8 July 2013; Accepted 27 August 2013

Academic Editors: J. Chen and K. R. Pennypacker

Copyright © 2013 Liming Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Regenerative strategies in treatment of stroke have great potential. The goal of the current study was to investigate safety of intrathecal administration of autologous CD34 positive cells in treatment of patients with poststroke. A total of eight male patients with a history of stroke were enrolled. The patients were treated subcutaneously with 5 μg/kg body weight rhG-CSF for 5 consecutive days, and then leukapheresis was performed to concentrate cells for CD34 positive immunoselection. All patients underwent intrathecal administration of CD34 positive cells via lumbar puncture. The primary outcome was safety evaluation for 12-month followup. In addition, behavioral function was evaluated with NIH stroke scale and Barthel index 1, 6, and 12 months after the last treatment, respectively. There were no major adverse events, and abnormal changes of blood tests during the whole treatment process included intrathecal administration and 12-month followup. The main message from the current study was that administration of G-CSF-mobilized autologous CD34 positive cells in patients with poststroke was safe. Future studies with larger population and control group are needed to confirm the safety and investigate the efficacy.